Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01308502
Other study ID # 09-007341
Secondary ID
Status Withdrawn
Phase Phase 4
First received March 2, 2011
Last updated March 29, 2012
Start date January 2010
Est. completion date January 2012

Study information

Verified date March 2012
Source Children's Hospital of Philadelphia
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the utility of a minimally invasive nasopharyngeal pH probe for the diagnosis of laryngopharyngeal reflux (LPR) in children with airway compromise; to determine whether it is comparable to the gold standard esophageal pH probe in identifying LPR in this population; and to correlate results of pH testing with validated questionnaires. Our hypothesis is that a nasopharyngeal pH probe is equivalent to an esophageal probe in identifying laryngopharyngeal reflux.


Description:

Laryngopharyngeal reflux (LPR) has been repeatedly linked to upper respiratory symptoms in the pediatric population. Children with LPR may present with laryngomalacia, subglottic stenosis, laryngitis, and vocal cord nodules among other illnesses. Pharyngeal reflux has even been implicated in causing common childhood illnesses such as sinusitis and otitis media. Diagnosing LPR can be difficult, especially in children. Often otolaryngologists depend on a general gestalt to diagnosis LPR. In some cases, physicians rely on a Reflux Symptoms Index (RSI) questionnaire filled out by the caretaker and/or a Reflux Finding Score (RFS) filled out by the practitioner. Others have attempted to use a variety of tools to measure pH in the upper airway and proximal esophagus.

Initial research focused on correlating gastroesophageal reflux (GER) with otolaryngologic illnesses. These studies relied mostly on esophageal pH probes placed at the lower esophageal sphincter. With the realization that extraesophageal reflux or LPR was a separate disease, new methods have developed to quantify it. The dual esophageal pH probe is the current gold standard for measuring LPR as it records pH just above the proximal esophageal sphincter. Conditions such as chronic pediatric sinusitis, otitis media, laryngitis and globus are believed to arise from laryngopharyngeal reflux. Unfortunately, this device fails to identify many patients with LPR who would benefit from treatment, and radiographic studies are limited by their short duration of evaluation and risk of radiation. In addition, the placement of the esophageal pH probe is relatively invasive requiring both sedation and x-rays to confirm placement. Finally, they are difficult to place and maintain in children, necessitating a hospital stay for 24 hours while data is collected. The alternative is empiric treatment with Histamine 2 blockers and/or Protein Pump Inhibitors for an extended course, which has been shown to improve symptoms in many of these patients but is not without risk.

The new Dx-pH nasopharyngeal probe is the only tool available for directly measuring nasopharyngeal pH. It is an exempted class I medical device and is Food and Drug Administration (FDA)-approved for general use in the population. The device, manufactured by Respiratory Technology Corporation ISO (ResTech), measures the pH of both liquid and aerosolized droplets. It is positioned posterior to the soft palate and placement is confirmed by visualizing the light-emitting diode (LED) at the tip of the device. It is significantly less invasive than esophageal pH probes, does not require general anesthesia for placement, and can be used in an outpatient setting.

The Dx-pH probe is currently being used clinically in adult and pediatric practices to diagnose and monitor laryngopharyngeal reflux with only limited research supporting its use. A literature review finds only 6 studies that address the Dx-pH probe, of which, only 1 pilot study has been performed in children. This study looked at changes in pH in the trachea of 3 children with chronic tracheostomies. However, to date, no research has been published on the utility of the probe in diagnosing LPR in children. The probe, if effective, would be a valuable tool for diagnosing LPR in the pediatric population because of its limited risk and potential ability to replace more invasive and costly procedures.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2012
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 1 Month to 17 Years
Eligibility Inclusion Criteria:

- History of airway compromise

- Undergoing microlaryngoscopy, bronchoscopy, esophagoscopy, and esophageal pH probe placement at CHOP

Exclusion Criteria:

- Patients not undergoing esophageal pH probe placement

- Neonates under 1 month of age

- Adults over 18 years of age or older.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Device:
Dx-pH probe
Dx-pH probe with 24 hour recording

Locations

Country Name City State
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Children's Hospital of Philadelphia

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary nasopharyngeal pH Change in nasopharyngeal pH as measured by the Dx-pH probe 24 hours No
See also
  Status Clinical Trial Phase
Recruiting NCT06205446 - Application of Diaphragmatic Breathing in Patients With Disorders of Gut-brain Interaction N/A
Completed NCT02552966 - Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin N/A
Completed NCT01450748 - Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux Phase 3
Recruiting NCT04827355 - Reflux Band in Laryngopharyngeal Reflux N/A
Not yet recruiting NCT03455803 - Effect of CPAP Therapy on LPR Among Patients With OSAS N/A
Withdrawn NCT02530879 - Comparison of Voice Therapy and Antireflex Therapy in LPR Phase 4
Completed NCT01854970 - Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux N/A
Completed NCT00321503 - Study of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR) N/A
Terminated NCT01317472 - The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux N/A
Completed NCT01880892 - Laryngopharyngeal Reflux Before and After Cricopharyngeal Myotomy N/A
Completed NCT02183961 - Three Methods Used in the Diagnosis of EER in Children With OME N/A
Not yet recruiting NCT01328652 - Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Phase 4
Not yet recruiting NCT04383262 - Lexiva for the Treatment of LPR Phase 3
Recruiting NCT04984304 - Individualized Diagnosis and Treatment of Extraesophageal Reflux in Patients With Chronic Cough N/A
Withdrawn NCT03463395 - Efficacy of Reza Band for the Treatment of Laryngopharyngeal Reflux N/A
Completed NCT00864396 - Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux Phase 1
Completed NCT03619811 - Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease N/A
Recruiting NCT05879029 - Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD Phase 4
Recruiting NCT05204303 - LPR Fluorescence Pilot
Terminated NCT01777854 - Anti-reflux Control to Decrease Post Tonsillectomy Pain Phase 4